Yahoo · Aug 12, 2026
TNDM Q2 Loss Narrower Than Expected, Revenues Miss, Stock Up
Tandem Diabetes shares jump 19.1% after a narrower-than-expected Q2 loss, as higher pump shipments and a 57% gross margin offset a slight revenue miss.
TN
NASDAQ · TNDM
Tandem Diabetes Care, Inc.
Healthcare · Medical - Devices
$22.57
Down-$0.89 (-3.79%)
Updated Aug 21, 2026, 12:44 PM
SID Score
5.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.42B
- P/E ratio
- -6.98
- Dividend yield
- 0.00%
- 52-week range
- $10.25 – $29.65
- Volume
- 1.82M
- Avg. volume
- 2.11M
Price performance
TNDM price history
1M range · 21 trading sessions · Daily adjusted prices
TNDM closed at $22.57 after 21 trading sessions, up 33.55% for the selected period.
- Last close
- $22.57
- Period change
- +33.55%
- Period low
- $16.90
- Period high
- $23.73
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 20, 2026 | $23.11 | $23.53 | $22.22 | $22.57 | 1.82M |
| Aug 19, 2026 | $24.20 | $24.81 | $23.42 | $23.46 | 1.66M |
| Aug 18, 2026 | $22.16 | $24.10 | $22.097 | $23.73 | 2.63M |
| Aug 17, 2026 | $22.50 | $22.94 | $21.70 | $22.255 | 1.38M |
| Aug 14, 2026 | $22.92 | $22.92 | $22.355 | $22.72 | 1.69M |
| Aug 13, 2026 | $23.33 | $23.555 | $22.88 | $23.13 | 1.42M |
| Aug 12, 2026 | $23.16 | $23.605 | $22.71 | $23.44 | 1.7M |
| Aug 11, 2026 | $22.615 | $23.80 | $22.559 | $23.44 | 1.78M |
| Aug 10, 2026 | $22.03 | $23.03 | $21.825 | $22.81 | 2.32M |
| Aug 7, 2026 | $17.39 | $22.65 | $17.07 | $22.38 | 5.44M |
| Aug 6, 2026 | $19.30 | $19.545 | $18.495 | $18.79 | 3.8M |
| Aug 5, 2026 | $19.25 | $19.86 | $19.00 | $19.59 | 3.47M |
| Aug 4, 2026 | $19.95 | $20.81 | $19.605 | $20.20 | 2.82M |
| Aug 3, 2026 | $19.82 | $20.50 | $19.725 | $20.11 | 3.33M |
| Jul 31, 2026 | $19.10 | $19.66 | $18.56 | $19.50 | 1.83M |
| Jul 30, 2026 | $18.31 | $19.04 | $18.0273 | $19.01 | 2.06M |
| Jul 29, 2026 | $17.79 | $18.745 | $17.424 | $18.59 | 1.91M |
| Jul 28, 2026 | $17.17 | $18.04 | $17.17 | $17.76 | 1.86M |
| Jul 27, 2026 | $17.13 | $17.27 | $16.34 | $17.17 | 1.58M |
| Jul 24, 2026 | $17.09 | $17.26 | $16.49 | $17.12 | 1.15M |
| Jul 23, 2026 | $16.93 | $17.09 | $16.14 | $16.90 | 1.16M |
Latest TNDM news
The latest Smart Investors Daily articles mentioning TNDM.
Stock researchCompany · Overview
TNDM research
Overview
Company profile and research snapshot.
Company profile
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $19.80
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | RBC Capital | Outperform | — |
| Aug 7, 2026 | Citigroup | Neutral | — |
| Jul 15, 2026 | Mizuho | Neutral | — |
| Jun 23, 2026 | Deutsche Bank | Hold | — |
| Jun 1, 2026 | Wells Fargo | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 11, 2026
Why Tandem Diabetes (TNDM) Stock Is Trading Up Today
Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) jumped 18.2% in the afternoon session after the company reported second-quarter results that showed improved profitability and a narrower-than-expected loss per share.
Yahoo · Aug 10, 2026
TNDM Q2 Deep Dive: Pharmacy Channel Gains and Pipeline Execution Amid Margin Recovery
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.8% year on year to $254.6 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $1.08 billion at the midpoint. Its non-GAAP loss of $0.31 per share was in line with analysts’ consensus estimates.
Yahoo · Aug 9, 2026
Why Tandem Diabetes Care (TNDM) Is Up 14.8% After Record Q2 Sales And PayGo Momentum
Tandem Diabetes Care reported past second-quarter 2026 results with record worldwide sales of US$254.56 million, higher gross margin of 57%, and a reduced net loss of US$21.17 million, while reaffirming full-year sales guidance of about US$1.07 billion. Momentum in the new PayGo pharmacy model, with roughly 10% of U.S. shipments and 45% formulary coverage, signaled a meaningful shift toward higher-visibility, recurring revenue streams and broader access for insulin pump users. Now we’ll...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
